A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma – Beigene

⟵ Back to Search Results

A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

Beigene Study ID

BGB-A317-203

ClinicalTrials.gov ID

NCT03209973

China Drug Trials ID

CTR20170119

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Study Documents

Study Protocol Statistical Analysis Plan